Paris, 23October 2014 - NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced the signing today of a financing project with Kepler Cheuvreux.

Neovacs has an innovative portfolio of vaccines in clinical and pre-clinical stage, which will need several years to develop until registration.

Some of these products should be subject of a licensing or co-development agreement, assuring, thus a long lasting scientific partnership as well as the cofinancing of common projects.

In addition and in order to accompany its plan of development, Neovacs has already been able to agree with Kepler Cheuvreux on a financing tool, covering several years, including optional items, in order to be able to raise funds according to the evolution of the company's financial needs.

Agreed in its principles by the management team of both companies, the implementation of this project will be a subject of a detailed information at a later stage.

distributed by